



# 4<sup>TH</sup> INTERNATIONAL WORKSHOP ON TUMOR EVOLUTION


*“Making the Impossible Possible:  
Successful Tackling of Difficult Targets  
in Cancer Research and Clinical Development”*



March 28-29, 2022  
Centro Formazione  
“R. Bastianelli”  
Via Fermo Ognibene, 23  
00144 Roma

**HYBRID  
MEETING**






## WELCOME MESSAGE

The past few decades have witnessed major advances in our understanding of cancer biology. Breakthroughs in genomic technologies, transcriptomic profiling leveraged at single cell level, functional characterization of genes boosted more recently by the advent of whole-genome CRISPR/Cas9 screens, have enhanced our identification of therapeutic targets. Unfortunately, many of the candidate genes that emerged from these studies have shown to be extremely difficult if not impossible to target.

KRAS, TP53, MYC, PTEN gene alterations are only a few examples of key drivers whose therapeutic targeting have not yet entered into clinical practice, with the notable exception of the recent development of KRAC G12C inhibitors for the treatment of non small cell lung cancer. In line with this brilliant example, this workshop focuses on showing how to “make the impossible possible: i.e. to successfully tackle difficult targets in cancer research and clinical development”. These ambitious goals require the combination of clever and sophisticated medicinal chemistry efforts aided by advanced structural biology as well as innovative clinical trials. In this regard, clinical trials act as a critical engine for the discovery and development of new therapies that have undergone massive re-wiring in the last decade. Indeed, they have shifted from traditional studies evaluating cytotoxic chemotherapy to histology-based populations conceived to be adaptively designed and biomarker-driven to evaluate precise molecular targeted and immunotherapies in selected patients subsets.

Unprecedented effort has been devoted to the generation of a framework that can promptly transform scientific discoveries in clinical practice through the application of innovative technologies and adaptive design methodologies.





**IRE**

ISTITUTO NAZIONALE TUMORI

**REGINA ELENA**

ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

**ORGANIZING COMMITTEE:**

**Gennaro Ciliberto, Federico Cappuzzo, Rita Falcioni, Giovanni Blandino**

**SECRETARIAT:**

**Tania Merlino, Carmela Matrascia, Roberto Bernardi**

**IRCCS Regina Elena National Cancer Institute (IRE)**

Via Elio Chianesi 53, 00144 (Rome, Italy)

T. +39 06 52662728 F. +39 06 52665523

E-mail: [dirscire@ifo.it](mailto:dirscire@ifo.it)

**ORGANIZING SECRETARIAT:**

**AIM Group International**

ROME OFFICE


Via Flaminia 1068 - 00189 Rome, Italy

T. +39 06330531

E-mail: [4thInternationalworkshop2022@aimgroup.eu](mailto:4thInternationalworkshop2022@aimgroup.eu)



# PROGRAMME



## **MONDAY, 28 MARCH 2022**

08.30 a.m. - 09.00 a.m.

**Marina Cerimele** - General Director of Istituti Fisioterapici Ospitalieri (IFO, Rome, Italy)

**Gennaro Ciliberto** - Scientific Director of Regina Elena National Cancer Institute (IRE, Rome, Italy)

### **WELCOME INTRODUCTION**

#### **WORKSHOP PART I**

#### **Young Investigators IRCCS Regina Elena National Cancer Institute (IRE, Rome, Italy)**

Chairperson: **Piera Tocci** (IRE, Rome, Italy)

09.00 a.m. - 09.15 a.m.

**Giulia Regazzo** (IRE, Rome, Italy)

A diagnostic serum miRNA signature governs cell invasion via TSK4/5 regulation in human gliomas

09.15 a.m. - 09.30 a.m.

**Federica Ganci** (IRE, Rome, Italy)

Identification of a circulating miRNAs signature as potential biomarker for predicting recurrence in head and neck cancer

09.30 a.m. - 09.45 a.m.

**Luigi Fattore** (IRE, Rome, Italy)

Therapeutic miRNAs to overcome resistance to therapy in melanoma

09.45 a.m. - 10.00 a.m.

**Giulia Bon** (IRE, Rome, Italy)

SEMA6A: a potential predictor of benefit from Dual BRAF/MEK inhibition in melanoma

10.00 a.m. - 10.15 a.m.

**Sara Donzelli** (IRE, Rome, Italy)

A living biobank of human breast cancer metastases to unveil driver genes and effective treatments

10.15 a.m. - 10.35 a.m.


**General Discussion**

*10.35 a.m. - 11.00 a.m.*

*Coffee Break*



# PROGRAMME



**MONDAY, 28 MARCH 2022**

## WORKSHOP PART I

**Young Investigators IRCCS Regina Elena National Cancer Institute (IRE, Rome, Italy)**

Chairperson: **Sara Donzelli** (IRE, Rome, Italy)

11.00 a.m.- 11.15 a.m.

**Piera Tocci** (IRE, Rome, Italy)

Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibitor

11.15 a.m.- 11.30 a.m.

**Marta Di Martile** (IRE, Rome, Italy)

Targeting the anti-apoptotic bcl-2 family proteins to improve cancer treatment

11.30 a.m. - 11.45 a.m.

**Eleonora Petti** (IRE, Rome, Italy)

TRF2: a novel therapeutic target in triple negative breast cancer

11.45 a.m. - 12.00 p.m

**Silvia Matteoni** (IRE, Rome, Italy)

Antipsychotics and cancer: could the “dirty drug” chlorpromazine prove effective in glioblastoma treatment?

12.00 p.m. - 12.15 p.m.

**Marcello Maugeri-Saccà** (IRE, Rome, Italy)

KEAP 1 mutations in lung cancer, a new molecular entity

12.15 p.m. 12.35 p.m.


**General Discussion**

*12.35 p.m. - 02.00 p.m.*

*Lunch*



# PROGRAMME



**MONDAY, 28 MARCH 2022**

## INTERNATIONAL WORKSHOP PART I

### 02.00 p.m. 02.30 p.m. WELCOME ADDRESS

**Giuseppe Ippolito** - General Director for Research and Innovation for Healthcare at Italian Ministry of Health (Rome, Italy)

**Aldo Morrone** Scientific Director of San Gallicano Dermatologic Institute (ISG, Rome, Italy)

**Gennaro Ciliberto** - Scientific Director of Regina Elena National Cancer Institute (IRE, Rome, Italy)

### SESSION I – RAS AND EGFR EXON 20

Chairpersons: **Federico Cappuzzo** (IRE, Rome, Italy) - **Silvia Giordano** (Turin, Italy)

02.30 p.m. - 03.00 p.m.

**Fabrice Barlesi** (Villejuif, France)

Why and how target KRAS in daily practice today?

03.00 p.m. - 03.30 p.m.

**Enriqueta Felip** (Barcelona, Spain)

Emerging treatment options for NSCLC with Exon 20 Insertion Mutations

03.30 p.m.- 04.00 p.m.

**Ferdinando Skoulidis** (Houston, USA)

Dissecting the clinical heterogeneity on KRAS-mutant NSCLC

04.00 p.m.-04.30 p.m.

**Davis S. Hong** (Houston, USA)

KRAS G12C-Next Steps: Combining KRAS G12C Inhibitors and Beyond

04.30 p.m. - 05.00 p.m.

**Natasha Leigh** (Toronto, Canada)

EGFRex20ins - initial learnings from the clinic

*05.00 p.m. - 05.30 p.m.*

*Coffee Break*

### SESSION II – OPTIMAL DRUG AND TARGET THERAPY

Chairperson: **Anna Bagnato** (IRE, Rome, Italy)

05.30 p.m. - 06.00 p.m.

**Ciara Metcalfe** (San Francisco, USA)

Next-Generation Estrogen Receptor Therapeutics for Breast Cancer


06.00 p.m. - 06.30 p.m.

**Julie R. Brahmer** (Baltimore, USA)

Combination immunotherapy strategies for Lung Cancer



# PROGRAMME



**TUESDAY, 29 MARCH 2022**

## Workshop Part II

**Young Investigators IRCCS Regina Elena National Cancer Institute (IRE, Rome, Italy)**

Chairperson: **Matteo Pallocca** (IRE, Rome, Italy)

10.00 a.m. - 10.15 a.m.

**Giulia Cristinziano** (IRE, Rome, Italy)

Generation and pre-clinical exploitation of cholangiocarcinoma mouse models driven by Fgfr2 fusions

10.15 a.m. - 10.30 a.m.

**Valentina Piastra** (IRE, Rome, Italy)

The MKK3/AURKA crosstalk fosters malignancy in colorectal cancer: implications for novel therapeutics approach

10.30 a.m. - 10.45 a.m.

**Matteo Allegretti** (IRE, Rome, Italy)

Impact of liquid biopsy in advanced HER2\* breast cancer

10.45 a.m. - 11.00 a.m.

**Francesca R. Auciello** (IRE, Rome, Italy)

Metabolism and tumor plasticity

11.00 a.m. - 11.15 a.m.

**Giulia Federici** (IRE, Rome, Italy)

p53 mitotic centrosome localization as a functional test to predict pathogenicity of ATM VUS

11.15 a.m. - 11.35 a.m.


**General Discussion**

*11.35 a.m. - 12.00 p.m.*

*Coffee Break*



# PROGRAMME



**TUESDAY, 29 MARCH 2022**

## Workshop Part II

**Young Investigators IRCCS Regina Elena National Cancer Institute (IRE, Rome, Italy)**

Chairperson: **Giulia Cristinziano** (IRE, Rome, Italy)

12.00 p.m. - 12.15 p.m.

**Annalisa Tocci** (IRE, Rome, Italy)

hMena splicing regulates cancer-specific type-I IFN signaling and pro-tumoral macrophages polarization in NSCLC

12.15 p.m. - 12.30 p.m.

**Francesca Paolini** (IRE, Rome, Italy)

In situ vaccine (ISV): the last frontier of cancer immunotherapy

12.30 p.m. - 12.45 p.m.

**Matteo Pallocca** (IRE, Rome, Italy)

Challenges from ultra-low input RNA-sequencing as companion diagnostic in solid tumors

12.45 p.m. - 01.00 p.m.

**Giacomo Corleone** (IRE, Rome, Italy)

Mapping the DNA accessibility landscape of B-ALL patients reveals principles of cancer evolution

01.00 p.m. - 01.20 p.m.

*General Discussion*


**01.20 p.m. - 03.00 p.m.**

*Lunch*





# PROGRAMME



**TUESDAY, 29 MARCH 2022**

## International Workshop Part II

### SESSION III - P53

Chairperson: **Silvia Soddu** (IRE, Rome, Italy)

03.00 p.m. - 03.30 p.m.

**Galina Selivanova** (Stockholm, Sweden)

Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity

03.30 p.m. - 04.00 p.m.

**Thomas Cluzeau** (Nice, France)

Eprenetapopt in TP53 mutated MDS/AML

### SESSION IV - EPIGENETIC DRUGS

Chairperson: **Alfredo Budillon** (Naples, Italy)

04.00 p.m. - 04.30 p.m.

**Sudha Rao** (Brisbane, Australia)

Eraser Enzymes & Epigenetic re-programming in metastatic breast cancer

04.30 p.m. - 05.00 p.m.

**Zariana Nikolova** (Neuchâtel, Switzerland)

Trotabresib (CC-90010, BMS-986378), a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients with high-grade gliomas

*05.00 p.m. - 05.30 p.m. Coffee Break*

### SESSION V - NEWS IN ONCOIMMUNOLOGY

Chairperson: **Paola Nisticò** (IRE, Rome, Italy)

05.30 p.m. - 06.00 p.m.

**Michele Maio** (Siena, Italy)

Tackling epigenetics for cancer immunotherapy


06.00 p.m. - 06.30 p.m.

**Davide Bedognetti** (Doha, Qatar)

AC-ICAM: an Atlas and Compass of Immune-Cancer-Microbiome Interactions in relationship to tumor evolution



# FACULTY

**Anna Bagnato**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Fabrice Barlesi**

Institut Gustave Roussy  
Villejuif, France

**Davide Bedognetti**

Sidra Medical and Research  
Center  
Doha, Qatar

**Giovanni Blandino**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Julie R. Brahmer**

Sidney Kimmel  
Comprehensive  
Cancer Center Johns Hopkins  
Baltimore, USA

**Alfredo Budillon**

IRCCS Pascale  
Naples, Italy

**Federico Cappuzzo**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Marina Cerimele**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Gennaro Ciliberto**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Thomas Cluzeau**

Cote D'azur University,  
Hematology  
Department, Nice University  
Hospital  
Nice, France

**Rita Falcioni**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy

**Enriqueta Felip**

Oncology Department of Vall  
d'Hebron University, Vall  
d'Hebron  
Institute of Oncology  
Barcelona, Spain

**Silvia Giordano**

University of Turin  
Turin, Italy

**Davis S. Hong**

Department of Investigational  
Cancer  
Therapeutics University of  
Texas  
Anderson Cancer Center  
Houston, USA

**Giuseppe Ippolito**

General Director for Research  
and  
Innovation for Healthcare at  
Italian  
Ministry of Health  
Rome, Italy

**Natasha Leigh**

University Health Network,  
Princess  
Margret Cancer Centre  
Toronto, Canada

**Michele Maio**

University of Siena, Center for  
Immuno-Oncology,  
Department  
of Oncology, University  
Hospital of Siena  
Siena, Italy

**Ciara Metcalfe**

Department of Translational  
Oncology,  
Genentech, South  
San Francisco, USA

**Aldo Morrone**

Scientific Director of San  
Gallicano  
Dermatologic Institute, ISG  
Rome, Italy

**Zariana Nikolova**

Celgene Clinical  
Research & Development  
Neuchâtel, Switzerland

**Paola Nisticò**

IRCCS Regina Elena  
National Cancer Institute  
Rome, Italy

**Sudha Rao**

QIMR Berghofer Medical  
Research Institute QIMRb  
Brisbane, Australia

**Galina Selivanova**

Department of Microbiology,  
Tumor and Cell Biology,  
Karolinska Institute  
Stockholm, Sweden


**Ferdinando Skoulidis**

University of Texas  
Anderson Cancer Center  
Houston, USA

**Silvia Soddu**

IRCCS Regina Elena National  
Cancer Institute  
Rome, Italy





## YOUNG INVESTIGATORS WORKSHOP

IRCCS Regina Elena National Cancer Institute, Rome, Italy

### PART I

**Giulia Bon**

Cellular Network and Molecular  
Therapeutic Target Unit

**Marta Di Martile**

Preclinical Models and New  
Therapeutic Agents Unit

**Sara Donzelli**

Oncogenomics and Epigenetics Unit

**Luigi Fattore**

SAFU Laboratory

**Federica Ganci**

Oncogenomics and Epigenetics Unit

**Silvia Matteoni**

Cellular Network and Molecular  
Therapeutic Target Unit

**Marcello Maugeri-Saccà**

Department of Medical Oncology 2 &  
Biostatistics,  
Bioinformatics and Clinical Trial Center

**Eleonora Petti**

Oncogenomics and Epigenetics Unit

**Giulia Regazzo**

Oncogenomics and Epigenetics Unit

**Piera Tocci**

Preclinical Models and New Therapeutic  
Agents Unit

### PART II

**Matteo Allegretti**

Oncogenomics and Epigenetics Unit

**Francesca R. Auciello**

Oncogenomics and Epigenetics Unit

**Giacomo Corleone**

SAFU Laboratory

**Giulia Cristinziano**

Oncogenomics and Epigenetics Unit

**Giulia Federici**

Cellular Network and Molecular  
Therapeutic Target Unit

**Matteo Pallocca**

Biostatistics, Bioinformatics  
and Clinical Trial Center

**Francesca Paolini**

Tumor Immunology  
and Immunotherapy Unit

**Valentina Piastra**


Oncogenomics and Epigenetics Unit

**Annalisa Tocci**

Tumor Immunology  
and Immunotherapy Unit



# GENERAL INFORMATION



## MEETING VENUE

The venue for the Meeting will be:

Centro Formazione “R. Bastianelli”, Via Fermo Ognibene n. 23, - 00144 Rome

## SECRETARIAT DURING THE MEETING

The Secretariat will be open at the following times:

- Monday, 28 March 2022, from 8.00 a.m. to 6.30 p.m.
- Tuesday, 29 March 2022, from 9.00 a.m. to 6.30 p.m.

## OFFICIAL LANGUAGE

The official language of the Meeting will be English.

## TECHNICAL FACILITIES

Facilities will be available for computer presentations and overhead projections. A business centre with PC (PowerPoint for Windows) will be available for the checking and preview of presentations. All speakers must take their presentations to the business centre at least one hour before the session starts.

## FACULTY SLIDE CENTRE OPENING HOURS

The centre will be open at the following times:

- Monday, 28 March 2022, from 8.00 a.m. to 6.30 p.m.
- Tuesday, 29 March 2022, from 9.00 a.m. to 6.30 p.m.

## COFFEE BREAKS

Coffee breaks will be held in the Meeting area

## HOW TO REGISTER TO THE EVENT

**REGISTRATION TO THE WORKSHOP IS FREE.**

Subscription is required. Please visit the website: [4thInternationalworkshop2022.webaimgroup.eu](http://4thInternationalworkshop2022.webaimgroup.eu).

Registration is allowed only for virtual attendance and for a maximum number of 950 users.

## JOIN THE EVENT in LIVE STREAMING

You can enjoy the LIVE STREAMING for free, on **March 28th and 29th, 2022.**

Further information will be provided soon

